Big Pharma Compliance Policies Can Add Trouble For Biotech Partners – Panel
Executive Summary
Biotechs should be wary of entering into copromotion partnerships with larger pharmaceutical firms that have onerous compliance policies, panelists suggested during a Feb. 12 roundtable at the Biotechnology Industry Organization CEO & Investor Conference in New York
You may also be interested in...
Pfizer To Monitor Off-Label Drug Use Under Neurontin Settlement
Pfizer will provide periodic reports to the HHS Inspector General about off-label use trends for its products under the May 13 settlement of an investigation into the company's promotion of Neurontin
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.